ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study (RITA-MI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03072199
Recruitment Status : Recruiting
First Posted : March 7, 2017
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
Papworth Hospital NHS Foundation Trust

Brief Summary:

RITA-MI aims to develop of a novel therapeutic concept to target the immune response in patients with acute myocardial infarction (MI) by depleting B-cells with a single injection of Rituximab which is approved for clinical use in cancer, autoimmune disease and inflammatory conditions. The goal is to re-purpose the drug, and translate the discovery into benefit for patients at high risk of cardiovascular events. Rituximab is expected to limit infarction size and improve the healing process, as complementary to other therapeutic strategies.

The applicants intend to perform a clinical study in patients with acute myocardial infarction (MI). The objective is to find the optimal dose (lowest dose with highest biological efficacy and best safety profile) for peripheral blood B cell depletion during the first 6 days after injection, and selective molecular signatures associated with improved heart function through analysis of peripheral blood samples.

The study rationale is to decrease the inflammatory reaction upon tissue necrosis following heart muscle ischemia.


Condition or disease Intervention/treatment Phase
Ischemic Heart Disease Myocardial Infarction Inflammation Drug: RiTUXimab Injection Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Phase 1/2 unblinded interventional dose escalation study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study
Actual Study Start Date : June 1, 2017
Estimated Primary Completion Date : December 1, 2018
Estimated Study Completion Date : May 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack
Drug Information available for: Rituximab

Arm Intervention/treatment
Experimental: Rituximab Drug: RiTUXimab Injection
Single dose of Rituximab given intravenously within 48hours of myocardial infarction




Primary Outcome Measures :
  1. Safety - Review of Adverse Events and Serious Adverse Events; [ Time Frame: 6month ]
    Adverse and serious adverse events will be reviewed by daily history taking and clinical examination of patients whilst they are an inpatient. Subsequently patients will be followed up on discharge daily until day 6 with telephone follow up. On days 6, 14 and 6month patients will be assess again in an outpatient setting where adverse events will be documented. There is additional follow telephone follow up at day 30. After each group of 6 patients are recruited and infused with rituximab, an independent Data and Safety Monitoring Board will review the clinical and biological data and their side effect profile, including adverse events.

  2. Safety - Clinically significant changes in biochemical and haematological markers [ Time Frame: 6month ]
    Biochemistry and haematology bloods will be taken daily after drug administration whilst an inpatient. Upon discharge bloods will be taken on days 6, 14 and 6month for further assessment. Any new abnormalities will be flagged. After each group of 6 patients are recruited and infused with rituximab, an independent Data and Safety Monitoring Board will review the clinical and biological data and their side effect profile, including adverse events.

  3. Safety - Clinically significant ECG changes [ Time Frame: 6month ]
    Arrhythmia will be assess as patients will have continued cardiac monitoring whilst an inpatient. ECGs will be performed daily whilst an inpatient and also during outpatient attendance. QTc will be assessed using the Bazett formula. After each group of 6 patients are recruited and infused with rituximab, an independent Data and Safety Monitoring Board will review the clinical and biological data and their side effect profile, including adverse events.


Secondary Outcome Measures :
  1. B cells [ Time Frame: Days 0, 6, 14 and 6months ]
    Circulating B cells count before, immediately after administration (30 mins and 6 hours), and extended follow up (6 days, 14 days and 6months)

  2. Cardiac biomarkers - Circulating inflammatory (hsCRP and IL6) and cardiovascular (BNP and Troponin) biomarkers. [ Time Frame: Days 0, 2 and 6 months ]
    These will be measure before the infusion and compared to after infusion on days 2, 6 and 6 months



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-75 years old
  • Acute anterior (left anterior descending artery) STEMI and successful primary percutaneous coronary intervention (PCI) with stent implantation in the culprit lesion during the first 24h after onset of symptoms

Exclusion Criteria:

  • A previous history of STEMI
  • Cardiogenic shock (systolic blood pressure <80 mm Hg, unresponsive to fluids, or necessitating catecholamines), electrical instability or severe congestive heart failure
  • Residual severe proximal bystander disease awaiting inpatient revascularisation
  • Corrected QT interval (QTc) > 500 msecs using Bazett's formula
  • Hematologic abnormalities (hemoglobin <10 g/dL or hematocrit <30%, platelet cell count of <100 x103/μL, white blood cell count <4 x103/μL)
  • Hypogammaglobulinaemia (defined as <3g/L of IgG)
  • Renal failure (estimated GFR by the MDRD formula < 45 ml/min/1.73m2);
  • Known hepatic failure or abnormal liver function tests at baseline (ALT > 2 x ULN).
  • Active or recurrent hepatitis (type B).
  • Known HIV infection
  • Current or previous tuberculosis (Chest X-Ray)
  • Current infections
  • Presence or history in the previous five years of an ongoing cancer, except in situ cancer of the cervix or basal cell carcinoma
  • Any oral or intravenous immunosuppressive treatment (other than concomitant 100 mg methylprednisolone), disease modifying drugs, or other immune modulatory monoclonal antibodies or immunodepleting therapy at any time
  • Allergy to rituximab or one of its excipients
  • Expected need for vaccination with a live attenuated vaccine during the study including incomplete vaccination courses.
  • Known or suspected pregnancy at screening or lactating woman
  • Women of childbearing age unless confirmed by direct questioning that they are reproductively sterile or post-menopausal
  • Participation in other clinical trials
  • Inability to comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03072199


Locations
United Kingdom
Papworth Hospital NHS Trust Recruiting
Cambridge, Cambridgeshire, United Kingdom, CB23 3RE
Contact: Sarah Fielding, PhD    01480 364181    sarah.fielding@papworth.nhs.uk   
Principal Investigator: Stephen Hoole, MD         
Sub-Investigator: Tian Zhao, MPhil         
Sub-Investigator: Ziad Mallat, PhD         
Sponsors and Collaborators
Papworth Hospital NHS Foundation Trust

Responsible Party: Papworth Hospital NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT03072199     History of Changes
Other Study ID Numbers: P02100
First Posted: March 7, 2017    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Papworth Hospital NHS Foundation Trust:
Rituximab
B cells

Additional relevant MeSH terms:
Inflammation
Infarction
Heart Diseases
Myocardial Infarction
Myocardial Ischemia
Coronary Artery Disease
ST Elevation Myocardial Infarction
Pathologic Processes
Ischemia
Necrosis
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases
Rituximab
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents